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Previous studies have shown bismuth subsalicylate (BSS) has antimicrobial properties, but few studies have
addressed the mechanism of action. Furthermore, following BSS ingestion other bismuth salts form throughout the
gastrointestinal tract including bismuth oxychloride (BiOCl) that also act upon enteric pathogens. To further understand
the antimicrobial activity of bismuth in infectious diarrhea, the antimicrobial effect of BSS and BiOCl on Clostridium
difficile, Salmonella, Shigella, Shiga toxin-producing Escherichia coli strains and norovirus (NoV) were measured. Bacterial
enteric pathogens in pure culture or in human fecal material were exposed to 35mg/ml BSS or BiOCl with or without a
vehicle suspension. BSS and BiOCl treated samples were quantified and visualized by transmission electron microscopy.
To measure the effect on NoV, reduction of infectious murine NoV (MNV), a surrogate for human NoV, and Norwalk
virus RNA levels were measured by viral plaque assay and RT-qPCR, respectively. BSS and BiOCl reduced bacterial
growth by 3–9 logs in all strains with majority resulting in populations of <10 cfu/ml within 24 h. Similar results were
found when fecal material was included. Microscopy images detected bismuth on bacterial membranes and within the
bacterial organisms at 30 min post-treatment. At 8.8mg/ml BSS and BiOCl reduced infectivity of MNV significantly by
2.7 and 2.0 log after 24 h of exposure. In addition, both BSS and BiOCl slightly reduced the level of Norwalk replicon-
bearing cells suggesting that bismuth may inhibit NoV in vivo. Collectively, our results confirm and build on existing
data that BSS has antimicrobial properties against a wide-range of diarrhea-causing pathogens.
Introduction
Bismuth subsalicylate (BSS), an insoluble salt that contains
a trivalent heavy metal and salicylic acid, has been used for
over 100 y to relieve several digestive ailments including diar-
rhea. Several studies have shown that BSS is safe and effective
in preventing and treating traveler’s diarrhea (TD). Dupont
et al. found that US students that acquired diarrhea in Mexico
and treated with BSS had significant reduction in number of
unformed stools and severity of associated symptoms.1 In simi-
lar cohorts, BSS prophylaxis prevented TD with a protection
rate >60%.2,3 Significant reduction in diarrhea rates also was
detected in Swiss travelers to West Africa and volunteers chal-
lenged with enterotoxigenic Escherichia coli (ETEC), a primary
cause of TD, when taking BSS prophylactically vs. placebo.4,5
To help explain the effectiveness of BSS in relieving infectious
diarrhea, in vitro experiments published in the 80s and 90s
have demonstrated this active drug possesses antimicrobial
properties against bacteria and viruses.6-9 Along with BSS,
other bismuth salts that form in the gastrointestinal (GI) tract
elicit similar activity. As BSS passes through the stomach, it
undergoes hydrolysis by stomach acid resulting in the release
of salicylate that gets absorbed into the bloodstream while the
bismuth remains in the GI tract forming other insoluble salts
including bismuth oxychloride (BiOCl).10 Despite these favor-
able results for BSS, the evidence describing the underlying
mechanisms of how BSS controls infectious diarrhea requires
further investigation.
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There are several bacterial pathogens that instigate infectious
diarrhea. Some of these bacteria have been studied in relation to
antimicrobial activity of bismuth, such as ETEC and Salmonella,
while other species and strains of enteric bacteria that are causing
public health concerns have not been evaluated to the same
extent. One example is Clostridium difficile, which has been a
major issue in hospitals, other healthcare facilities and in the
community. C. difficile infections are difficult to eradicate with
antibiotics, and morbidity and mortality rates of C. difficile asso-
ciated-diarrhea have risen dramatically in the last decade.11-15
Contributing to this increased incidence is a new antibiotic-resis-
tant hypervirulent strain that is emerging in hospitals and, alarm-
ingly, infecting healthy individuals out in the community.16,17
Over the last 30 y another pathogen that has been problematic
for healthcare providers is Shiga toxin-producing E. coli (STEC),
most notably E. coli O157:H7. It is estimated that this strain has
caused 17 outbreaks and 75,000 illnesses each year in the US.18
Although the incidence rate has decreased considerably over the
last few years due to improved prevention and surveillance strate-
gies, E. coli O157:H7 is still among the top 5 pathogens contrib-
uting to foodborne hospitalizations.19,20 Other than rehydration
therapy, there is no specific treatment for this type of infection
and antibiotics are not recommended as they may increase the
risk of hemolytic uremic syndrome (HUS). Another STEC sero-
type, O104:H4, has recently gained public attention when it
caused the 2011 outbreak in Germany with 3,950 illnesses, 908
HUS cases and 53 deaths.21,22 As with O157:H7, the O104:H4
strain causes HUS even in the presence of antibiotic therapy. In
addition to the lack of data regarding bismuth activity on these
pathogens, the in vitro studies mentioned above have only inves-
tigated the antimicrobial effect of bismuth on pure cultures.
While this is the first logical step of assessing any antibacterial
compound, single-specie cultures are extremely different from
the GI environment where trillions of microorganisms reside.
Another major pathogen of infectious diarrhea is human nor-
ovirus (NoV). NoV is the leading cause of epidemic acute gastro-
enteritis and causes 50% of all diarrheal outbreaks
worldwide.23,24 The economic burden of NoV infections is esti-
mated to be greater than $2 billion including healthcare expenses
and loss of productivity. As a NoV vaccine is not available yet,
implementation of personal and environmental hygiene is recom-
mended to prevent NoV infections.25 In a previous clinical study
of inoculated healthy volunteers, BSS has been shown to be able
to reduce the severity and duration of NoV symptoms, although
the mechanism has yet to be elucidated.26
To further study how BSS and BiOCl may control infectious
diarrhea, we evaluated their effect on several key enteric patho-
gens using conventional and molecular methods.
Results
MICs of BSS C/¡ vehicle and BiOCl C/¡ vehicle on
common bacterial enteric pathogens
The MICs for BSS C/¡ vehicle ranged from 2–8 mg/ml
while the BiOClC/¡ vehicle MICs were 4–64 mg/ml (Table 1).
The MICs of BiOCl C/¡ vehicle were 2- to 8-fold higher com-
pared to MICs of BSS C/¡ vehicle. SS alone had similar MICs
to BSS C/¡ vehicle at 2–4 mg/ml. C. difficile was the most sus-
ceptible organism tested to the bismuth agents having the lowest
MIC of 4 mg/ml for BiOCl and low end MICs (2–8 mg/ml) for
the other 3 bismuth treatments compared to the Gram-negative
pathogens.
Establishment of Soleris to replace conventional plate counts
for in vitro antimicrobial assay
Soleris is a rapid optical instrument, formerly known as BioSys,
that has the capability of indirectly measuring CO2 production
from bacteria in a closed vial system (see Materials and Methods).
The amount of CO2 produced is proportional to the amount of
bacteria in a sample. Precision and accuracy of Soleris to measure
various bacterial concentrations in samples were evaluated by gener-
ating 3 standard curves with fresh cultures of ETEC in a BSSCve-
hicle background and comparing them to standard plate counts
(Fig. 1). BSSCvehicle was the background of choice because it was
the most complex matrix out of the 4 bismuth preparations. The
detection times produced by Soleris for each 10-fold dilution were
within 0.8 h as indicated by the narrow error bars. The detection
times from Soleris also were strongly correlated with the results
from plate counts with an R2-value >0.99. The average exponential
equation from the 3 standard curves was y D (5.7 £ 109)¡1.007x,
Table 1. Susceptibilities of various enteric pathogens to bismuth subsalicy-
late (BSS)C/¡ vehicle, bismuth oxychloride (BiOCl)C/¡ vehicle and sodium
salicylate (SS)
MIC (mg/ml)
Organism BSS BiOCl BSSCVehicle BiOClCVehicle SS
ETEC 8 16–32 4–8 32–64 2–4
S. Typhimurium 4–8 16–32 4–8 8–32 4
S. sonnei 2–8 16–32 4 16–32 4
C. difficile 2 4 4 8 4
Figure 1. Correlation of plate count results and Soleris detection times
for serial dilutions of ETEC. Each ( ) represents the mean § SEM for
each dilution run in triplicate.
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where x is the detection time and y is the bacterial concentration in
cfu/ml. This equation was utilized to convert detection times to
cfu/ml for the in vitro antimicrobial assay with ETEC.
Bacteriostatic and bactericidal activity of BSS C/¡ vehicle
and BiOCl C/¡ vehicle on enteric pathogens
An in vitro antibacterial assay was performed to track the
activity of BSS C/¡ vehicle and BiOCl C/¡ vehicle (35 mg/ml)
over time against common bacterial pathogens that cause diar-
rhea. Furthermore, a rapid and less labor intensive technology,
Soleris, was utilized in place of serial dilutions and plate counts
to quantify the concentration of ETEC in each sample. Results
from Soleris show that BSS C/¡ vehicle and BiOCl significantly
reduced viable numbers of ETEC over a 48 h period (Fig. 2). By
24–48 h no bacteria were detected with those 3 treatments indi-
cating <10 cfu/ml were present in the flask as the lower limit of
detection for this assay is 10 cfu/ml. Although BiOClCvehicle
never did achieve undetectable levels of bacteria and the viable
numbers remained constant over the period of 2 to 24 h, the
results were still statistically significant and there was a 3-log
reduction of ETEC compared to the untreated control by 48 h.
For the other bacterial species tested and quantified by plate
counts, the bismuth treatments at 35 mg/ml reduced bacterial
growth by 3–9 logs when compared to the control at 24 h of
exposure (Table 2 and Fig. S1). More than half (65%) of the
experimental trials resulted in no bacterial growth on the agar
plates, again indicating <10 cfu/ml were present. This signifies
that the bismuth preparations were able to eliminate 99.99%
of the initial inoculum within 24 h. BSS C/¡ vehicle was more
potent than the hydrolyzed forms against Shigella sonnei, and
BiOCl had minimal activity against E. coli O157:H7 compared
to the other treatments. All bismuth forms had similar toxicity at
24 h against C. difficile, E. coli O104:H21, and Salmonella
Typhimurium. C. difficile was the most susceptible pathogen;
within 2–8 h of exposure to each treatment no bacteria were
detected. S. Typhimurium was second most susceptible with no
detectable bacteria within 8–24 h of exposure to each treatment.
Although the results from the bismuth treatments at 17.5 mg/ml
were not as dramatic as the 35 mg/ml concentration, they had
similar inhibitory effects against the pathogens (data not shown).
When a complex fecal environment was introduced to the
assay, the bismuth complexes at 35 mg/ml maintained their anti-
bacterial activity toward the pathogens. Eighty-three percent of
the experimental runs resulted in the bismuth agents eradicating
the bacterial pathogens below the lower level of detection
(Table 3 and Fig. S2). Only S. sonnei was still detected after 24 h
when it was exposed to BiOCl and BSSCvehicle, but with a >3
log reduction vs. the control.
Binding of BSS to ETEC and accumulation within bacterial
cells
To complement the results from the in vitro antibacterial
assay, TEM analysis was conducted to visualize how BSS
interacts with bacteria at the cellular level. In 0.5 h of BSS
treatment, multiple dark particles were bound to the surface
of ETEC and had penetrated into the cells (Fig. 3). Similar
results also were detected at 4 and 8 h of exposure. These
dense particles continued to accumulate within the bacterial
cells indicated by the growing number and size of the par-
ticles at 24 h. Energy dispersive X-ray spectrometry con-
firmed that the dark particles attached to the bacterial cell
membrane and located within the bacteria were bismuth
(Fig. S3).
Interference effect of bismuth on entry of murine norovirus
in RAW 267.4 cells
At 0.1 mg/ml bismuth compounds did not affect the plaque
formation of murine norovirus (MNV; Table 4), whereas at
>2.1 mg/ml they resulted in cytotoxicity of the RAW 267.4 cells.
Between 0.5─2.1 mg/ml BSS and BSSCvehicle was able to
Figure 2. Soleris results from the in vitro antibacterial assay with ETEC are
depicted as the mean log cfu/ml § SEM for untreated and treated bac-
teria over a 48 h period. All bismuth treatments were tested at 35 mg/
ml. (*p < 0.05)
Table 2. Log reduction of bacterial growth vs. control at 24 h of treatment
(35 mg/ml)
Organism BSS BiOCl BSSCVehicle BiOClCVehicle
S. Typhimurium 9.0 9.0 9.0 9.0
S. sonnei 9.3 6.5 9.3 4.5
C. difficile 7.4 7.4 7.4 7.4
E. coli O157:H7 8.0 3.2 8.0 8.0
E. coli O104:H21 5.8 3.3 3.1 4.0
Table 3. Log reduction of bacterial growth vs. control at 24 h of treatment
(35mg/ml) in a fecal environment
Organism BSS BiOCl BSSCVehicle BiOClCVehicle
S. Typhimurium 7.4 7.4 7.4 7.4
S. sonnei 6.4 3.3 3.5 6.4
C. difficile 7.2 7.2 7.2 7.2
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reduce the number of MNV plaques by 98.0% and 85.9% (p
<0.05), respectively (Table 4). At 2.1 mg/ml BiOCl reduced
infectious MNV by 48.3% (p <0.05) while BiOClCvehicle had
little effect.
Effect of bismuth on MNV
Infectivity of untreated MNV (PBS control) was reduced
by 1.2 and 1.8 log10 PFU/ml after 24 and 48 h at 37
C,
respectively. At 2.1 mg/ml none of the bismuth compounds
statistically affected MNV infectivity compared to untreated
PBS control (Table 5). However, when treated with BSS or
BiOCl at 8.8 mg/ml, MNV infectivity was reduced by 2.7
and 2.0 log10 after 24 h and by 3.0 and 2.9 log10 after 48 h
of exposure, respectively (Table 5). In contrast, after exposure
to BSSCvehicle or BiOClCvehicle MNV infectivity was not
reduced compared to untreated controls.
The effect of bismuth on the replication of Norwalk virus
replicon in HG 23 cells
The effect of BSS C/¡ vehicle and BiOCl C/¡ vehicle on
Norwalk replicon-bearing HG 23 cells was examined (data not
shown). Incubation with bismuth com-
pounds at concentrations higher than
0.26 mg/ml resulted in cytotoxicity of
the HG cells. Exposure to BSS and
BiOCl at concentrations ranging from
0.004 to 0.13 mg/ml reduced the level
of Norwalk RNA copies in HG cells by
47.3% compared to mock treatment
(p< 0.05). BSSCvehicle resulted in
reduction of Norwalk virus RNA when
tested between 0.03 and 0.13 mg/ml (p
< 0.05).
Discussion
BSS and BiOCl possess antimicro-
bial properties against common diar-
rhea-causing pathogens by inhibiting
bacterial growth or killing the bacteria,
or with respect to viruses it can prevent
viral invasion of host cells and deter
viral replication. A few studies from the
1980s–90s have demonstrated the antimicrobial effects of BSS
on enteric pathogens, but the in-vitro antimicrobial data is not
available for several important pathogens.6–9 In addition, little
attention was focused on the relative contribution of BiOCl,
which is an additional form of bismuth in the small and large
intestine where the pathogens would be residing. In comparison
to the current MICs presented here, Cornick et al. reported anal-
ogous MICs for BSS and SS on similar genera and species of bac-
teria, but MICs for BiOCl were not done.6 The most likely cause
for the BSS C/¡ vehicle MICs to be lower than the BiOCl C/¡
vehicle MICs is removal of the salicylate from bismuth during
hydrolysis. It is known salicylates have antimicrobial effects on
bacteria and per MIC results salicylate alone has equivalent
potency as BSSC/¡ vehicle.6,27,28 This does not suggest bismuth
lacks antimicrobial activity because clearly it does in the form of
BiOCl as shown in the MIC, antibacterial and NoV assays. Fur-
thermore, the antimicrobial effects of salicylate on enteric patho-
gens in the lower GI tract are irrelevant in vivo as after salicylate
disassociates from bismuth in the stomach nearly all of it is
absorbed into the bloodstream whereas >99% of bismuth
Figure 3. TEM images of ETEC cells that were incubated in media with or without 0.35 mg/ml BSS at
0.5, 4, 8, and 24 h. Bismuth particles (indicated by arrows) bound to bacterial membrane and accumu-
lated within the cells.
Table 4. Norovirus reduction vs. control at 1.5 h post-infection
Reduction § SD (%) of MNV 1
Concentration of test ingredient (mg/ml) BSS BiOCl BSSCVehicle BiOClCVehicle
0.1 4.9 § 10.9 2.9 § 8.6 11.7 § 16.8 3.4 § 8.6
0.3 30.0 § 28.2* 7.6 § 20.0 26.8 § 30.0 17.3 § 29.4
0.5 98.0 § 13.8* 31.4 § 32.5 85.9 § 15.8* 36.7 § 33.4
1.1 100 § 6.0* 29.1 § 27.1 98.0 § 2.6* 6.8 § 13.6
2.1 100 § 0.0* 48.3 § 34.1* 100 § 0.0* 26.7 § 26.4
1 percentage reduction of infectious MNV in treated cells compared to mock-infected cells
* p <0.05 vs. untreated cells
96 Volume 6 Issue 2Gut Microbes
remains within the GI tract after each dose.10 C. difficile, a Gram-
positive microbe, was the most susceptible to the bismuth insults
compared to the other 3 pathogens that are Gram-negative. This
implies that the antibacterial activity of BSS and BiOCl is influ-
enced by the physiological structure of the bacterial cell wall;
however more Gram-positive and Gram-negative strains need to
be tested to confirm this notion.
Soleris has been used successfully in food and consumer prod-
ucts industries to rapidly determine the presence or absence of
microbes in finished products. For our in vitro antibacterial assay,
Soleris was used to replace conventional plating because it was
faster, cheaper and less labor intensive. The values generated by
Soleris for the standard curves were strongly correlated to ETEC
concentrations determined by plate counts and were even consis-
tent on separate days with different cultures. With the standard
curves an average exponential equation was able to be calculated
and utilized for quantifying bacteria in the unknown experimen-
tal samples. To our knowledge, this is the first published study to
use Soleris with this mathematical approach for enumerating bac-
teria. This technology allowed for multiple trials to be done more
quickly and easily for statistical analysis.
The in vitro antibacterial assay found that BSS and BiOCl
inhibited bacterial growth or reduced viable numbers below ini-
tial values in as little as 2–24 h. This time frame parallels what
has been observed in clinical studies for diarrhea relief.2,29 Man-
hart found similar inhibition from BSS on ETEC, Salmonella,
Shigella and some rare clinical isolates in a dose-dependent man-
ner ranging from 0.35–17.5 mg/ml.7 The current study gener-
ated comparable results for all bismuth treatments at 17.5 mg/
ml. When the concentration was doubled to 35 mg/ml, which is
equivalent to or higher than the majority of MICs that were mea-
sured, it drastically decreased the number of organisms in a 24 h
period. Furthermore, these results were reproducible when fecal
material with GI microflora was introduced. The plethora of
microorganisms from the fecal slurry could have acted as compet-
itive inhibitors on the bismuth and reduce its activity toward the
pathogens, but this did not occur in our assay.
Besides the common enteric species (ETEC, Salmonella, Shi-
gella) that were tested in the past with bismuth, other current and
emerging strains related to public health also were included in
the antibacterial assay. BSS and BiOCl had relative effects on C.
difficile, E. coli O157:H7, and E. coli O104:H21. As expected
from the MICs, C. difficile was the most susceptible pathogen to
the bismuth challenges in the antibacterial assay with both pure
culture and fecal slurries. These pathogens can cause severe to
fatal illness and can be difficult to treat with antibiotics. These
new findings suggest that BSS could be used as an alternative to
antibiotics in treating these problematic diseases, or in conjunc-
tion with antibiotic therapy as is the recommended strategy for
resolving Helicobacter pylori infections.30 More in vivo testing
would need to be done in animal models and clinical trials to
confirm efficacy of BSS against these specific infections, but
nonetheless an area that is worth exploring.
The TEM images provide visual evidence of how bismuth
from BSS interacts with a common enteric pathogen over time.
BSS has the ability to bind to the bacterial membrane of ETEC
and accumulate within the cells in as little as 0.5 h of exposure,
and this activity continues to occur over 24 h. These images cor-
relate well with the antibacterial data where bacterial growth is
inhibited by 8 h and bacteria are eradicated by 24 h, and they
are consistent with previously published ultrastructural images
generated to show bismuth interacting with bacteria. Electron
microscopy images of H. pylori and Yersinia enterocolitica exposed
to BSS, and C. difficile incubated with a synthetic bismuth com-
pound showed bismuth deposits on the membrane and inside
the bacteria within one hr resulting in bactericidal activity.31-33
There is evidence that bismuth may exert its antibacterial activity
by a number of mechanisms including cell wall degradation,
inhibiting plasma membrane function and hindering protein and
ATP synthesis.8,34-36 However, more specific insights on the cel-
lular targeting by bismuth in its molecular level interactions
remain to be investigated.
In addition to antibacterial affects, BSS and BiOCl also
showed antiviral activity. Similar to a previous study with rotavi-
rus,9 BSS and BSSCvehicle at 0.5 mg/ml reduced MNV infec-
tion possibly by inhibition of the attachment to its host cells.
Though BiOCl is much weaker in inhibiting MNV plaque for-
mation compared to BSS, both BSS and BiOCl concentrations
as low as 0.004 mg/ml were able to reduce Norwalk RNA levels.
However, it remains unclear how relevant these results are for a
potential in vivo treatment of NoV infections. Additional clinical
trials using modern methods will better clarify this in vitro antivi-
ral activity of BSS.
In conclusion, BSS and BiOCl that is generated in the diges-
tive tract as BSS passes through the stomach have similar antimi-
crobial effects on various enteric bacterial pathogens within 24 h
of exposure, which confirms data from previous clinical studies.
BSS and BiOCl also have antiviral activity against NoV as dem-
onstrated by the data from our MNV and Norwalk virus replicon
studies. Collectively, our results confirm and build on existing
data that BSS has antimicrobial properties against a wide-range
of diarrhea-causing pathogens.
Table 5. Antimicrobial activity of bismuth on murine norovirus
Reduction of infectivity § SD (log10 PFU)
Concentration of test ingredient (mg/ml) Contact time (hr) BSS BiOCl BSSCVehicle BiOClCVehicle
2.1 24 1.2 § 0.7 0.8 § 0.4 0.4 § 0.2 0.5 § 0.2
48 2.2 § 0.8 1.6 § 0.3 1.1 § 0.5 1.2 § 0.5
8.8 24 2.7 § 0.2* 2.0 § 0.2* 0.7 § 0.2 0.6 § 0.2
48 3.0 § 0.3* 2.9 § 1.0* 1.2 § 0.1 1.2 § 0.6




Dry powder USP grade BSS was manufactured by Procter &
Gamble Co. (Cincinnati, OH). BSSCvehicle solution consisted
of the active ingredient suspended in magnesium aluminum sili-
cate and methylcellulose with preservatives, flavoring and dyes
(Pepto-Bismol, Procter & Gamble Co.). Sodium salicylate (SS)
and all components for fasted state simulated gastric fluid
(FaSSGF) and taurocholate-cefoxitin-cycloserine-fructose agar
(TCCFA) were purchased from Sigma-Aldrich Corp. For hydro-
lyzing BSS, 10 g of BSS was stirred for 1 h in 500 ml of FaSSGF
(pH 1.6) composed of 34.2 mM sodium chloride, 0.08 mM
sodium taurochlate, 0.02 mM lecithin and 0.1 mg/ml pepsin in
sterile water. Afterwards, the precipitate was allowed to settle, the
top clear solution was decanted, and the bottom solution with
precipitate was centrifuged and washed twice with sterile water.
The remaining precipitate was weighed and resuspended with
sterile water to a specific concentration. Four-hundred ml of
BSSCvehicle containing 7g of BSS was hydrolyzed and prepared
in a similar fashion with 600 ml FaSSGF. More than 99% of the
hydrolyzed BSS C/¡vehicle was confirmed to be bismuth oxy-
chloride (BiOCl) by X-ray diffraction analysis using a Bruker D8
Advance diffractometer.
Bacterial and viral strains
All bacterial agents were purchased from American Type
Culture Collection and included Clostridium difficile (BAA-
1382; clinical isolate from Switzerland that contains toxin A
and toxin B genes), enterotoxigenic Escherichia coli (ETEC,
ATCC 31705), E. coli O157:H7 (ATCC 35150), E. coli
O104:H21 (BAA-178; STEC strain isolated from a 1994
Montana outbreak), Salmonella enterica serovar Typhimurium
(ATCC 13311), and Shigella sonnei (ATCC 11836). Before
each experiment, one ml of frozen bacterial stock was thawed
and transferred to 90 ml of trypticase-soy broth (TSB; BD
Difco) and incubated in a 5% CO2 incubator at 37
oC for
16 h except C. difficile, which was cultivated in brain heart
infusion broth (BHI; BD Difco) with 10% L-cysteine
(Sigma-Aldrich) and incubated in an anaerobic chamber at
37oC for 48 h. Liquid cultures then were centrifuged at
16,000 x g for 5 min, resuspended in saline or appropriate
growth media and the optical density adjusted to 1.0 at
610nm (»3–5 £ 108 cfu/ml). Initial bacterial concentrations
were confirmed by standard serial dilution and plate counts
on trypticase-soy agar (TSA; BD Difco) or BHI agar (BD
Difco) with 10% L-cysteine.
Strain CW3 of murine NoV (MNV) was used as a surrogate
for human NoV and propagated in RAW 264.7 cells (ATCC#
TIB-71) using Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% low endotoxin fetal bovine serum
(Hyclone Laboratories), 100 U/liter penicillin and 100 mg/liter
streptomycin, 1 mM HEPES, and 1 mM of sodium pyruvate, as
previously described.37 Aliquots of MNV with a viral titer of
106.6 PFU/ml were stored at ¡80C and thawed only once.
Minimum inhibitory concentration agar dilution assay
Minimum inhibitory concentrations (MIC) for BSS C/¡
vehicle and BiOCl C/¡ vehicle were measured by the Clinical
and Laboratory Standards Institute agar dilution assay due to the
high insolubility of the bismuth salts in liquid media.38 Briefly,
BSS C/¡ vehicle and BiOCl C/¡ vehicle were diluted by 2-fold
increments in liquid TSA or BHIC10% L-cysteine agar in a total
volume of 15 ml at concentrations ranging from 0.5 to 256 mg/
ml. Plates were poured and allowed to cool and dry. Prepared
cultures of C. difficile, ETEC, S. Typhimurium and S. sonnei
were diluted 1:100 in saline followed by spot inoculating each
plate with 10 ml of 104 cfu. After the spot inoculations dried,
plates were incubated appropriately and the presence or absence
of bacterial growth was examined at 24 h for the aerobes and at
48 h for C. difficile to determine the MIC.
In vitro antibacterial assay
Flasks containing 30 ml of TSB or BHIC10% L-cysteine
with or without BSS C/¡ vehicle or BiOCl C/¡ vehicle at con-
centrations of 17.5 mg/ml or 35 mg/ml were inoculated sepa-
rately with »106–107 cfu of each bacterial strain. The bismuth
concentrations were chosen based on the concentrations found in
BSS-containing products that are on the market. Flasks then
were incubated under optimal growth conditions for each strain
on an orbital shaker at 250 rpm for 24 h. One ml aliquot sam-
ples were collected from each flask at 0, 2, 4, 8, 24, and 48 h
post-inoculation. Samples were neutralized and diluted 1:10 in
modified letheen broth with 1.5% tween 80 (MLBT; BD Difco),
serially diluted in saline and cultured onto appropriate agar plates
to acquire a cfu/ml concentration.
To simulate the complex environment of the lower GI tract,
the assay was repeated with the addition of gut microflora via
fecal slurries and incubating the flasks under anaerobic condi-
tions. Approximately 106–107 cfu of C. difficile, S. Typhimurium
or S. sonnei were added to flasks containing 15 ml of media with
or without one of the 4 bismuth treatments at 35 mg/ml and
15 ml of 200 mg/ml of pooled fecal material homogenized in
saline buffer from 4 healthy volunteers. Flasks were incubated at
37oC in an anaerobic chamber while shaking. After samples were
neutralized and serially diluted they were plated on selective-dif-
ferential agar. C. difficile was quantified on self-made TCCFA.
This was prepared by adding 40g proteose peptone 3, 5g
Na2HPO4, 1g KH2PO4, 2g NaCl, 0.1g MgSO4, 6g fructose,
and 20g agar to 1L of water and then autoclaved. Afterwards 1g
taurcholate, 0.25g D-cycloserine, and 16mg cefoxitin were com-
bined with the liquid agar. SS agar (BD Difco) was used to quan-
tify S. Typhimurium and S. sonnei.
Soleris (Neogen, Lansing, MI), a rapid optical instrument for-
merly known as BioSys, also was utilized for this assay with a
pure culture of ETEC to replace standard serial dilution and plat-
ing. Soleris has the capability of indirectly measuring CO2 pro-
duction, which is proportional to the amount of bacteria in the
sample, by using a closed vial system containing MLBT with 1%
lecithin (MLBTL) and a liquid indicator that changes from blue
to yellow as CO2 levels are elevated. Three standard curves were
generated on separate days with fresh cultures of ETEC and
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compared to conventional plate counts. Each standard curve con-
sisted of NF-MLBTL vials (Neogen) with one ml of BSSCvehicle
to serve as background matrix and inoculated with 10-fold dilu-
tions of ETEC. The vials were inserted into the Soleris machine
and incubated for 48 h at 33oC. Using Soleris Microbiological
System v6.1.2f software, the threshold was set at 12 with a skip
factor of one. Standard curves were plotted as cfu/ml from plate
counts vs. detection time in hr from Soleris and best fit exponen-
tial equations were calculated. The in vitro assay was repeated
3 times with ETEC as described above. Samples were neutralized
1:10 in NF-MLBTL vials and analyzed by Soleris under the same
conditions and settings as the standard curves. The average of the
3 exponential equations from the standard curves then was used
to convert detection times to cfu/ml.
Electron microscopy and energy dispersion spectrometry
analysis
For transmission electron microscopy (TEM), 108 cfu of
ETEC were exposed to 0.35 mg/ml BSS in TSB at 37oC while
shaking. The 0.35mg/ml concentration was chosen because
higher concentrations gave too much background noise and
proved difficult to visualize the bacterial cells in the TEM images.
At 0.5, 4, 8, and 24 h of exposure bacterial aliquots were fixed in
2.5% glutaraldehyde in 0.1M cacodylate buffer for one hr at
room temperature, and washed and centrifuged (16,000 £ g for
5 min) 3 times with 0.1M cacodylate buffer. Samples then were
stained with 1% osmium tetroxide in 0.1M cacodylate buffer,
dehydrated in increasing concentrations of acetone followed by
infiltration with increasing concentrations of Embed-It (Poly-
sciences Inc.) and cured overnight at 65oC. Next, 70 nm sections
were cut by a Reichert-Jung Ultra E ultramicrotome (Buffalo,
NY) with a diamond knife and placed on a 100 mesh nickel grid.
Finally, all sections were examined by a Hitachi S-5200 STEM
at 30KeV with PCI software (Tokyo, Japan) for imaging analysis
and a Burker Esprit 1.9 for energy dispersive X-ray spectrometry
for elemental analysis to confirm the presence of bismuth.
NoV interference assay
Confluent monolayers of raw cells were infected with a mixture
of 100 PFU of MNV and bismuth compounds in concentrations
ranging from 0.1 to 17.5 mg/ml and incubated for 1.5 h at 37C.
Viral plaques were enumerated as described previously.37 The dif-
ference in viral titer between bismuth compound-treated cells and
untreated cells was compared. Uninfected cells were used to deter-
mine possible cytotoxicity of the bismuth compounds.
MNV plaque assay
A suspension test was used to measure the virucidal effect of
bismuth solutions on MNV as described previously.37 Briefly,
0.9 ml of each bismuth compound (BSS C/¡ vehicle and BiOCl
C/¡ vehicle) at 2 concentrations (8.8 and 2.1 mg/ml) was mixed
with 0.1 ml of MNV, and incubated at 37C. After 24 and 48 h,
100 ml of the bismuth-virus mixture was transferred into 900 ml
of PBS containing 10% fetal bovine serum (PBS-F), followed by
the centrifugation at 12,000 x g for 1 min. Each supernatant was
10-fold serially diluted in PBS-F and assayed by plaque assay. At
least 6 replicates from 3 independent experiments were analyzed
for each variable.
Norwalk virus replication inhibition assay
Huh-7 based Norwalk virus replicon-bearing cells (HG23 cells),
kindly provided by Dr. Chang (Kansas State University), were
propagated in Dulbecco’s modified Eagle medium containing 10%
fetal bovine serum (HyClone Laboratories), 1% nonessential amino
acids, 100 units/ml penicillin, 100 mg/ml streptomycin, and 1 mg/
ml geneticin (DMEM; Life Technologies). The human NoV repli-
con system (HG23 cells), consisting of a human liver cell line trans-
fected with human NoV RNA, was used to assess the dose response
of each compound on the Norwalk replication level.39 Specifically,
HG cells were seeded at the density of 2£ 105 replicon cells in 96-
well plates and incubated at 37oC. After 24 h, culture medium was
aspirated, and replenished with 100 ml of DMEM having one of
the bismuth compounds (BSSC/¡ vehicle or BiOClC/¡ vehicle)
ranging from 0.0003 to 2.13 mg/ml. After incubation for 48 h,
cells were washed 3 times with PBS, lysed and viral RNA was
extracted using a total RNA extraction kit (Life Technologies).
NoV RNA was measured by RT-qPCR as described previously.40
Morphological changes or cytotoxic effect of bismuth compound
treated HG23 cells were monitored daily by light microscopy up to
7 d. To compensate for intra- and inter-kinetic RT-qPCR varia-
tions, ß-actin RNA was used to normalize results as described
previously.39
Statistical Analysis
Student t-tests were conducted on the results from the anti-
bacterial assay with Soleris by comparing control samples to each
of the 4 bismuth-treated samples for each time point. The effect
of the bismuth compounds on MNV plaque formation and Nor-
walk replicon RNA levels were analyzed with one-way analysis of
variance (ANOVA) using PASW Statistic 18 (IBM SPSS Inc.,
New York, NY).41 Each pairwise treatment comparison was sta-
tistically tested at a significance level of 5%.
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